Anthracyclines, such as doxorubicin (DOX), are well known for their high efficacy in treating multiple cancers, but their clinical usage is limited due to their potential to induce fatal cardiotoxicity. Such detrimental effects significantly impact the overall physical condition or even induce the morbidity and mortality of cancer survivors. Therefore, it is extremely important to understand the mechanisms of DOX-induced cardiotoxicity to develop methods for the early detection of cytotoxicity and therapeutic applications. Studies have shown that many molecular events are involved in DOX-induced cardiotoxicity. However, the precise mechanisms are still not completely understood. Recently, noncoding RNAs (ncRNAs) have been extensively studied in a diverse range of regulatory roles in cellular physiological and pathological processes. With respect to their roles in DOX-induced cardiotoxicity, microRNAs (miRNAs) are the most widely studied, and studies have focused on the regulatory roles of long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), which have been shown to have significant functions in the cardiovascular system. Recent discoveries on the roles of ncRNAs in DOX-induced cardiotoxicity have prompted extensive interest in exploring candidate ncRNAs for utilization as potential therapeutic targets and/or diagnostic biomarkers. This review presents the frontier studies on the roles of ncRNAs in DOX-induced cardiotoxicity, addresses the possibility and prospects of using ncRNAs as diagnostic biomarkers or therapeutic targets, and discusses the possible reasons for related discrepancies and limitations of their use.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52:1213–25.
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14.
Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by nadh dehydrogenase. J Biol Chem. 1986;261:3060–7.
Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 2002;1588:94–101.
Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol. 1998;30:243–54.
Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circ Res. 2000;86:8–14.
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.
Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
Wang JX, Zhang XJ, Feng C, Sun T, Wang K, Wang Y, et al. Microrna-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis. 2015;6:e1677.
Zhao L, Qi Y, Xu L, Tao X, Han X, Yin L, et al. Microrna-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting nrf2 and sirt2. Redox Biol. 2018;15:284–96.
Ambros V. Micrornas: tiny regulators with great potential. Cell. 2001;107:823–6.
Hutvagner G, Zamore PD. A microrna in a multiple-turnover rnai enzyme complex. Science. 2002;297:2056–60.
Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking mirna-1-2. Cell. 2007;129:303–17.
van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–32.
Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, et al. Reciprocal regulation of microrna-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009;120:2377–85.
Wang Y, Zhang Q, Wei C, Zhao L, Guo X, Cui X, et al. Mir-378 modulates energy imbalance and apoptosis of mitochondria induced by doxorubicin. Am J Transl Res. 2018;10:3600–9.
Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789–92.
Delpy E, Hatem SN, Andrieu N, de Vaumas C, Henaff M, Rucker-Martin C, et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res. 1999;43:398–407.
Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem Pharmacol. 1980;29:3003–10.
Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun. 2009;378:450–5.
Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and bcl-2:Bax ratio. Cancer Res. 2002;62:4592–8.
Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121:2012–22.
Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on h9c2 myoblasts: Nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol. 2009;25:227–43.
Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP, et al. Mir-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med. 2011;17:71–8.
Wan Q, Xu T, Ding W, Zhang X, Ji X, Yu T, et al. Mir-499-5p attenuates mitochondrial fission and cell apoptosis via p21 in doxorubicin cardiotoxicity. Front Genet. 2018;9:734.
Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, et al. Acute doxorubicin cardiotoxicity is associated with mir-146a-induced inhibition of the neuregulin-erbb pathway. Cardiovasc Res. 2010;87:656–64.
Jing X, Yang J, Jiang L, Chen J, Wang H. Microrna-29b regulates the mitochondria-dependent apoptotic pathway by targeting bax in doxorubicin cardiotoxicity. Cell Physiol Biochem. 2018;48:692–704.
Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin ii-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488–96.
Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 2009;296:H1466–83.
Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. Ii. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068–74.
Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtdna and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003;108:2423–9.
Wallace KB, Sardao VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126:926–41.
Wan GX, Cheng L, Qin HL, Zhang YZ, Wang LY, Zhang YG. Mir-15b-5p is involved in doxorubicin-induced cardiotoxicity via inhibiting bmpr1a signal in h9c2 cardiomyocyte. Cardiovasc Toxicol. 2019;19:264–75.
Du J, Hang P, Pan Y, Feng B, Zheng Y, Chen T, et al. Inhibition of mir-23a attenuates doxorubicin-induced mitochondria-dependent cardiomyocyte apoptosis by targeting the pgc-1alpha/drp1 pathway. Toxicol Appl Pharmacol. 2019;369:73–81.
Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L, et al. Myocardial mir-30 downregulation triggered by doxorubicin drives alterations in beta-adrenergic signaling and enhances apoptosis. Cell Death Dis. 2015;6:e1754.
Regula KM, Ens K, Kirshenbaum LA. Inducible expression of bnip3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res. 2002;91:226–31.
Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994;89:2829–35.
Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253–60.
Li J, Wan W, Chen T, Tong S, Jiang X, Liu W. Mir-451 silencing inhibited doxorubicin exposure-induced cardiotoxicity in mice. Biomed Res Int. 2019;2019:1528278.
Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene. 2008;27:285–99.
Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S, et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest. 1993;91:1697–705.
Gupta SK, Garg A, Avramopoulos P, Engelhardt S, Streckfuss-Bomeke K, Batkai S, et al. Mir-212/132 cluster modulation prevents doxorubicin-mediated atrophy and cardiotoxicity. Mol Ther. 2019;27:17–28.
Tony H, Yu K, Qiutang Z. Microrna-208a silencing attenuates doxorubicin induced myocyte apoptosis and cardiac dysfunction. Oxid Med Cell Longev. 2015;2015:597032.
Tong Z, Jiang B, Wu Y, Liu Y, Li Y, Gao M, et al. Mir-21 protected cardiomyocytes against doxorubicin-induced apoptosis by targeting btg2. Int J Mol Sci. 2015;16:14511–25.
Zhu JN, Fu YH, Hu ZQ, Li WY, Tang CM, Fei HW, et al. Activation of mir-34a-5p/sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity. Sci Rep. 2017;7:11879.
Pakravan G, Foroughmand AM, Peymani M, Ghaedi K, Hashemi M-S, Hajjari M, et al. Downregulation of mir-130a, antagonized doxorubicin-induced cardiotoxicity via increasing the pparγ expression in mescs-derived cardiac cells. Cell Death Dis. 2018;9:758.
Fu J, Peng C, Wang W, Jin H, Tang Q, Wei X. Let-7 g is involved in doxorubicin induced myocardial injury. Environ Toxicol Pharmacol. 2012;33:312–7.
Yin Z, Zhao Y, Li H, Yan M, Zhou L, Chen C, et al. Mir-320a mediates doxorubicin-induced cardiotoxicity by targeting vegf signal pathway. Aging (Albany NY). 2016;8:192–207.
Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci. 2018;3:861–70.
Octavia Y, Kararigas G, de Boer M, Chrifi I, Kietadisorn R, Swinnen M, et al. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. J Cell Mol Med. 2017;21:3277–87.
Fernandez-Fernandez A, Carvajal DA, Lei T, McGoron AJ. Chemotherapy-induced changes in cardiac capillary permeability measured by fluorescent multiple indicator dilution. Ann Biomed Eng. 2014;42:2405–15.
Wilkinson EL, Sidaway JE, Cross MJ. Cardiotoxic drugs herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability. Biol Open. 2016;5:1362–70.
Batista PJ, Chang HY. Long noncoding rnas: cellular address codes in development and disease. Cell. 2013;152:1298–307.
Mercer TR, Dinger ME, Mattick JS. Long non-coding rnas: insights into functions. Nat Rev Genet. 2009;10:155–9.
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human hox loci by noncoding rnas. Cell. 2007;129:1311–23.
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding rna controls muscle differentiation by functioning as a competing endogenous rna. Cell. 2011;147:358–69.
Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, et al. A long noncoding rna protects the heart from pathological hypertrophy. Nature. 2014;514:102–6.
Thum T, Condorelli G. Long noncoding rnas and micrornas in cardiovascular pathophysiology. Circ Res. 2015;116:751–62.
Xie Z, Xia W, Hou M. Long intergenic noncoding rnap21 mediates cardiac senescence via the wnt/betacatenin signaling pathway in doxorubicin-induced cardiotoxicity. Mol Med Rep. 2018;17:2695–704.
Li J, Li L, Li X, Wu S. Long noncoding rna linc00339 aggravates doxorubicin-induced cardiomyocyte apoptosis by targeting mir-484. Biochem Biophys Res Commun. 2018;503:3038–43.
Chen L, Yan KP, Liu XC, Wang W, Li C, Li M, et al. Valsartan regulates tgf-beta/smads and tgf-beta/p38 pathways through lncrna chrf to improve doxorubicin-induced heart failure. Arch Pharmacol Res. 2018;41:101–9.
Li HQ, Wu YB, Yin CS, Chen L, Zhang Q, Hu LQ. Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding mhrt rna expression. Biomed Pharmacother. 2016;81:474–81.
Zhang S, Yuan Y, Zhang Z, Guo J, Li J, Zhao K, et al. Lncrna foxc2-as1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of wnt1-inducible signaling pathway protein-1. Biosci Biotechnol Biochem. 2019;83:653–8.
Nigro JM, Cho KR, Fearon ER, Kern SE, Ruppert JM, Oliner JD, et al. Scrambled exons. Cell. 1991;64:607–13.
Chen CY, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular rnas. Science. 1995;268:415–7.
Li M, Ding W, Sun T, Tariq MA, Xu T, Li P, et al. Biogenesis of circular rnas and their roles in cardiovascular development and pathology. FEBS J. 2018;285:220–32.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural rna circles function as efficient microrna sponges. Nature. 2013;495:384–8.
Gupta SK, Garg A, Bar C, Chatterjee S, Foinquinos A, Milting H, et al. Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular rna expression. Circ Res. 2018;122:246–54.
Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, et al. A circular rna protects the heart from pathological hypertrophy and heart failure by targeting mir-223. Eur Heart J. 2016;37:2602–11.
Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The rna binding protein quaking regulates formation of circrnas. Cell. 2015;160:1125–34.
Guo W, Jiang T, Lian C, Wang H, Zheng Q, Ma H. Qki deficiency promotes foxo1 mediated nitrosative stress and endoplasmic reticulum stress contributing to increased vulnerability to ischemic injury in diabetic heart. J Mol Cell Cardiol. 2014;75:131–40.
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–31.
Ruggeri C, Gioffre S, Chiesa M, Buzzetti M, Milano G, Scopece A, et al. A specific circulating microrna cluster is associated to late differential cardiac response to doxorubicin-induced cardiotoxicity in vivo. Dis Markers. 2018;2018:8395651.
Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986;46:3722–7.
Desai VG, J CK, Vijay V, Moland CL, Herman EH, Lee T, et al. Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicol Appl Pharmacol. 2014;281:221–9.
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microrna spectrum in 12 body fluids. Clin Chem. 2010;56:1733–41.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating micrornas as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating micrornas independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–8.
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. Micrornas are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–33.
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mrnas and micrornas is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.
Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating cell-free microrna-1 in acute myocardial infarction. Clin Sci (Lond). 2010;119:87–95.
Danielson KM, Shah R, Yeri A, Liu X, Camacho Garcia F, Silverman M, et al. Plasma circulating extracellular rnas in left ventricular remodeling post-myocardial infarction. EBioMedicine. 2018;32:172–81.
Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microrna-1 and microrna-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011;4:446–54.
Nishimura Y, Kondo C, Morikawa Y, Tonomura Y, Torii M, Yamate J, et al. Plasma mir-208 as a useful biomarker for drug-induced cardiotoxicity in rats. J Appl Toxicol. 2015;35:173–80.
Ruggeri C, Gioffre S, Achilli F, Colombo GI, D’Alessandra Y. Role of micrornas in doxorubicin-induced cardiotoxicity: An overview of preclinical models and cancer patients. Heart Fail Rev. 2018;23:109–22.
Rigaud VO, Ferreira LR, Ayub-Ferreira SM, Avila MS, Brandao SM, Cruz FD, et al. Circulating mir-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. Oncotarget. 2017;8:6994–7002.
Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PP, Winick NJ. Circulating micrornas: potential markers of cardiotoxicity in children and young adults treated with anthracycline chemotherapy. J Am Heart Assoc. 2017;6:e004653.
Oatmen KE, Toro-Salazar OH, Hauser K, Zellars KN, Mason KC, Hor K, et al. Identification of a novel microrna profile in pediatric patients with cancer treated with anthracycline chemotherapy. Am J Physiol Heart Circ Physiol. 2018;315:H1443–52.
Vacchi-Suzzi C, Bauer Y, Berridge BR, Bongiovanni S, Gerrish K, Hamadeh HK, et al. Perturbation of micrornas in rat heart during chronic doxorubicin treatment. PLoS ONE. 2012;7:e40395.
Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum micrornas in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48:61–9.
He Z, Yang JJ, Zhang R, Li HT, Wu L, Jiang F, et al. Circulating mir-29b positively correlates with non-alcoholic fatty liver disease in a chinese population. J Dig Dis. 2019;20:189–95.
Huang Y, Tang S, Huang C, Chen J, Li J, Cai A, et al. Circulating mirna29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy. Clin Exp Hypertens. 2017;39:119–25.
Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 esc position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the esc committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (esc). Eur Heart J. 2016;37:2768–801.
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.
Temming P, Qureshi A, Hardt J, Leiper AD, Levitt G, Ancliff PJ, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the united kingdom. Pediatr Blood Cancer. 2011;56:625–30.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of micrornas in vivo with ‘antagomirs’. Nature. 2005;438:685–9.
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of hcv infection by targeting microrna. N. Engl J Med. 2013;368:1685–94.
van Rooij E, Olson EN. Microrna therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Disco. 2012;11:860–72.
Dalpke A, Helm M. Rna mediated toll-like receptor stimulation in health and disease. RNA Biol. 2012;9:828–42.
Lesizza P, Prosdocimo G, Martinelli V, Sinagra G, Zacchigna S, Giacca M. Single-dose intracardiac injection of pro-regenerative micrornas improves cardiac function after myocardial infarction. Circ Res. 2017;120:1298–304.
Chang H, Yi B, Ma R, Zhang X, Zhao H, Xi Y. CRISPR/cas9, a novel genomic tool to knock down microrna in vitro and in vivo. Sci Rep. 2016;6:22312.
Di Mauro V, Iafisco M, Salvarani N, Vacchiano M, Carullo P, Ramirez-Rodriguez GB, et al. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of micrornas. Nanomed (Lond). 2016;11:891–906.
Kopechek JA, McTiernan CF, Chen X, Zhu J, Mburu M, Feroze R, et al. Ultrasound and microbubble-targeted delivery of a microrna inhibitor to the heart suppresses cardiac hypertrophy and preserves cardiac function. Theranostics. 2019;9:7088–98.
Song Y, Zhang C, Zhang J, Jiao Z, Dong N, Wang G, et al. Localized injection of mirna-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction. Theranostics. 2019;9:2346–60.
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, et al. Identification of circulating microrna signatures for breast cancer detection. Clin Cancer Res. 2013;19:4477–87.
Fan J, Yin Z, Xu J, Wu F, Huang Q, Yang L, et al. Circulating micrornas predict the response to anti-pd-1 therapy in non-small cell lung cancer. Genomics. 2020;112:2063–71.
de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast Cancer Res Treat. 2020;179:161–71.
Zhao Z, He J, Zhang J, Liu M, Yang S, Li N, et al. Dysregulated mir1254 and mir579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer. Tumour Biol. 2014;35:5227–35.
Zhou F, Lu X, Zhang X. Serum mir-30c level predicted cardiotoxicity in non-small cell lung cancer patients treated with bevacizumab. Cardiovasc Toxicol. 2018;18:284–9.
Li L, Zhang M, Chen W, Wang R, Ye Z, Wang Y, et al. Lncrna-hotair inhibition aggravates oxidative stress-induced h9c2 cells injury through suppression of mmp2 by mir-125. Acta Biochim Biophys Sin (Shanghai). 2018;50:996–1006.
Li M, Ding W, Tariq MA, Chang W, Zhang X, Xu W, et al. A circular transcript of ncx1 gene mediates ischemic myocardial injury by targeting mir-133a-3p. Theranostics. 2018;8:5855–69.
Zou X, Wang J, Tang L, Wen Q. Lncrna tug1 contributes to cardiac hypertrophy via regulating mir-29b-3p. Vitr Cell Dev Biol Anim. 2019;55:482–90.
Wang X, Wang L, Ma Z, Liang W, Li J, Li Y, et al. Early expressed circulating long noncoding rna chast is associated with cardiac contractile function in patients with acute myocardial infarction. Int J Cardiol. 2020;302:15–20.
Vausort M, Salgado-Somoza A, Zhang L, Leszek P, Scholz M, Teren A, et al. Myocardial infarction-associated circular rna predicting left ventricular dysfunction. J Am Coll Cardiol. 2016;68:1247–8.
Zhao Z, Li X, Gao C, Jian D, Hao P, Rao L, et al. Peripheral blood circular rna hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Sci Rep. 2017;7:39918.
This work was supported by the Natural Science Foundation of Shandong Province (Grant no. JQ201815), National Natural Science Foundation of China (Grant no. 81770232), and a grant from Fu Wai Hospital (No. 2019kf-03).
The authors declare no competing interests.
About this article
Cite this article
Fa, Hg., Chang, Wg., Zhang, Xj. et al. Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets. Acta Pharmacol Sin 42, 499–507 (2021). https://doi.org/10.1038/s41401-020-0471-x
- noncoding RNAs